Trial Profile

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Nov 2020 Results from XANTUS, XANAP, GLORIA-AF, ETNA AF-Europe, ETNA AF-Korea/Taiwan, ETNA AF-Japan, comapring stroke and bleeding outcomes in Asia and Europe patients with Nonvalvular Atrial Fibrillation, presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
08 Sep 2020 Results of this sub-analysis assessing the effect of gender on outcomes published in the Clinical Cardiology
30 Aug 2017 Results of pooled analysis of three observational studies (XANTUS, XANAP and XANTUS-EL) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com